DRUG · Mapped RxNorm record
Docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
NCT00429871
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Capecitabine
Normalized identity: capecitabineView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Epirubicin
Normalized identity: epirubicinView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedRandomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
DocetaxelDRUG · verified · RxNorm: docetaxel
CapecitabineDRUG · verified · RxNorm: capecitabine
EpirubicinDRUG · verified · RxNorm: epirubicin
DocetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
Hellenic Oncology Research Grouplead sponsor
University Hospital of Cretecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00429871 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.